Dr. Katherine Linder, MD

Dr. Linder practices at Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health.

Dr. Linder's NPI, 1417358367, was assigned on September 10, 2014. Dr. Linder holds New Jersey license 25MA11186900.

Dr. Linder's primary practice is Hackensack University Medical Center, at 30 Prospect Ave, Hackensack, NJ 07601 in Bergen County. The practice phone is (551) 996-2000.

Dr. Linder's primary practice is Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health. Dr. Linder is also affiliated with Jersey Shore University Medical Center. The medical group on file is Regional Cancer Care Associates. Dmand AI also links Dr. Linder to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Linder practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Linder's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Linder is licensed in New Jersey.

CMS data shows 8,765 Medicare services from Dr. Linder across 12 procedure codes in 2024, for 327 Medicare patients. Medicare paid $267,637 for them.

CMS counts 327 Medicare patients who saw Dr. Linder in 2024. The largest group is 65 to 74, with 131 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 3.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Linder's median patient age at 66, with 51% women.

In 2024, Dr. Linder wrote 617 Medicare Part D claims for 130 patients. 62% of them were for generic drugs. CMS names the drug for 417 of them, across 14 drugs with 11 or more claims each, at $2,078,988 in total drug cost. In 2023, CMS named 433 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Linder for performance year 2024. Dr. Linder accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Linder, published from 2011 to 2021. 2017 was the busiest year, with 2. Dr. Linder has published most often in Biomark Res. Dr. Linder's most frequent co-authors are Oleg Epelbaum, MD, Chaitanya Iragavarapu, MBBS and Gabriela Andries, MD.

CMS Open Payments shows 115 general payments to Dr. Linder from 26 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $256.